drugset
drugset / Trial / NCT04037618

Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-EYP001a After a Single Oral Dose

NCT04037618 ↗

Phase 1 Completed 6 enrolled Enyo Pharma
NaSingle-groupOpen-labelTreatment

Summary

The study is designed to investigate the absorption, metabolism, and excretion of EYP001a as well as the safety/tolerability of EYP001a following the administration of a single oral dose to healthy male volunteers. The EYP001a dose is administered in a \[14C\]-labeled form to enable detection and quantitation of dose-related material independent of possible biotransformation.

Timeline

Start
2019-07-24
Primary completion
2019-07-27
Completion
2019-08-06

Drugs

EvaluationDrugModalityDoseRoute
Subject EYP001a Unknown — Oral

Indications

No indication recorded.